Comirnaty COVID-19 mRNA vaccine: standardized template with key considerations for a benefit-risk assessment
Thrombosis with Thrombocytopenia Syndrome (TTS) and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment
Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment
Modified Vaccinia Ankara (MVA) vaccine platform: standardized template for collection of key information for risk/benefit assessment
BC Case Definition: Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM) (Korean Translation)
Medigen COVID-19 protein vaccine: standardized template with key considerations for a benefit/risk assessment
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Inactivated viral vaccine against Chikungunya virus: standardized template with key considerations for a benefit/risk assessment
Moderna COVID-19 Vaccine (mRNA-1273): standardized template with key considerations for a benefit/risk assessment
Soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses: standardized template
Inactivated Viral Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment
BC Publication: The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) (Chinese Translation)
Protein Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment
Nucleic Acid (RNA And DNA) Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment Author links open overlay panel
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment
Reference set for performance testing of pediatric vaccine safety signal detection methods and systems
Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women
Guidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy
Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment
Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions
Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies
Editorial: The development of standardized case definitions and guidelines for adverse events following immunization
Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)
